Dia Medica Therapeutics Inc. DMAC
We take great care to ensure that the data presented and summarized in this overview for DiaMedica Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DMAC
View all-
Vanguard Group Inc Valley Forge, PA1.54MShares$10.9 Million0.0% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX650KShares$4.63 Million4.32% of portfolio
-
Geode Capital Management, LLC Boston, MA630KShares$4.49 Million0.0% of portfolio
-
First Manhattan CO New York, NY606KShares$4.32 Million0.01% of portfolio
-
Bleichroeder LP New York, NY382KShares$2.72 Million0.47% of portfolio
-
Northern Trust Corp Chicago, IL325KShares$2.31 Million0.0% of portfolio
-
State Street Corp Boston, MA252KShares$1.79 Million0.0% of portfolio
-
Morgan Stanley New York, NY240KShares$1.71 Million0.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC198KShares$1.41 Million0.0% of portfolio
-
Jacob Asset Management Of New York LLC Hermosa Beach, CA169KShares$1.2 Million0.62% of portfolio
Latest Institutional Activity in DMAC
Top Purchases
Top Sells
About DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Insider Transactions at DMAC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 27
2025
|
Jan Stahlberg > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,772
+0.65%
|
$304,632
$6.0 P/Share
|
|
Aug 26
2025
|
Jan Stahlberg > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
59,648
+0.77%
|
$357,888
$6.0 P/Share
|
|
Aug 25
2025
|
Jan Stahlberg > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
338,265
+4.23%
|
$2,029,590
$6.0 P/Share
|
|
Aug 22
2025
|
Jan Stahlberg > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
59,788
+0.81%
|
$298,940
$5.96 P/Share
|
|
Aug 21
2025
|
Jan Stahlberg > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
48,172
+0.66%
|
$240,860
$5.96 P/Share
|
|
Aug 20
2025
|
Jan Stahlberg > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
71,107
+0.98%
|
$355,535
$5.86 P/Share
|
|
Aug 15
2025
|
Jan Stahlberg > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,233
+0.12%
|
$49,398
$6.0 P/Share
|
|
Aug 14
2025
|
Jan Stahlberg > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
70,414
+0.98%
|
$352,070
$5.99 P/Share
|
|
Aug 13
2025
|
Jan Stahlberg > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
293,601
+3.99%
|
$1,468,005
$5.91 P/Share
|
|
Jul 23
2025
|
Jan Stahlberg > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,542,857
+18.57%
|
$4,628,571
$3.5 P/Share
|
|
Jul 23
2025
|
Thomas Von Koch > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,857,142
+25.42%
|
$8,571,426
$3.5 P/Share
|
|
Jul 23
2025
|
Richard Jacinto Ii > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
400,000
+7.46%
|
$1,200,000
$3.5 P/Share
|
|
Apr 07
2025
|
Richard D. Pilnik Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+7.12%
|
$48,000
$2.11 P/Share
|
|
Feb 13
2025
|
Randall Michael Giuffre Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+2.13%
|
$34,000
$2.88 P/Share
|
|
Jan 02
2025
|
James T. Parsons Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,917
+17.34%
|
$79,585
$5.34 P/Share
|
|
Jan 02
2025
|
Randall Michael Giuffre Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,861
+2.81%
|
$54,305
$5.34 P/Share
|
|
Jan 02
2025
|
Richard Kuntz Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,925
+29.08%
|
$49,625
$5.34 P/Share
|
|
Jan 02
2025
|
Richard D. Pilnik Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,393
+3.47%
|
$51,965
$5.34 P/Share
|
|
Jan 02
2025
|
Charles Pauling Semba Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,290
+10.6%
|
$26,450
$5.34 P/Share
|
|
Jun 28
2024
|
Jan Stahlberg > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,200,000
+18.69%
|
$2,400,000
$2.5 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 52.4K shares |
|---|---|
| Open market or private purchase | 5.8M shares |
| Exercise of conversion of derivative security | 41K shares |